Table 3 Treatment-related adverse events.
Events | Cohort A (N = 18) | Cohort B (N = 11) | ||
|---|---|---|---|---|
All grades | Grade 3–4 | All grades | Grade 3–4 | |
N (%) | N (%) | N (%) | N (%) | |
Hypothyroidism | 6 (33%) | 0 (0%) | 2 (18%) | 0 (0%) |
Hyperthyroidism | 5 (28%) | 0 (0%) | 1 (9%) | 0 (0%) |
Rash | 4 (22%) | 0 (0%) | 0 (0%) | 0 (0%) |
Stomatitis | 2 (11%) | 0 (0%) | 0 (0%) | 0 (0%) |
Malaise | 2 (11%) | 0 (0%) | 0 (0%) | 0 (0%) |
Fever | 2 (11%) | 0 (0%) | 0 (0%) | 0 (0%) |
Diarrhea | 1 (6%) | 0 (0%) | 1 (9%) | 0 (0%) |
Nausea | 1 (6%) | 0 (0%) | 1 (9%) | 0 (0%) |
Abdominal pain | 1 (6%) | 0 (0%) | 0 (0%) | 0 (0%) |
Colitis | 1 (6%) | 0 (0%) | 0 (0%) | 0 (0%) |
Edema | 1 (6%) | 0 (0%) | 0 (0%) | 0 (0%) |
GGT increased | 1 (6%) | 0 (0%) | 0 (0%) | 0 (0%) |
Lymphocyte count decreased | 1 (6%) | 0 (0%) | 0 (0%) | 0 (0%) |
Hyperglycemia | 1 (6%) | 0 (0%) | 0 (0%) | 0 (0%) |
Headache | 1 (6%) | 0 (0%) | 0 (0%) | 0 (0%) |
Pruritus | 1 (6%) | 0 (0%) | 0 (0%) | 0 (0%) |
Skin induration | 1 (6%) | 0 (0%) | 0 (0%) | 0 (0%) |
Fatigue | 0 (0%) | 0 (0%) | 1 (9%) | 0 (0%) |
Aspartate aminotransferase increased | 0 (0%) | 0 (0%) | 1 (9%) | 1 (9%) |
Alanine aminotransferase increased | 0 (0%) | 0 (0%) | 1 (9%) | 0 (0%) |
Blood bilirubin increased | 0 (0%) | 0 (0%) | 1 (9%) | 0 (0%) |
Alkaline phosphatase increased | 0 (0%) | 0 (0%) | 1 (9%) | 0 (0%) |
Dyspnea | 0 (0%) | 0 (0%) | 1 (9%) | 0 (0%) |
